| Bioactivity | HUHS015 is a potent prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitor with an IC50 of 0.67μM for PCA-1[1]. | ||||||||||||
| Target | IC50: 0.67 μM (PCA-1) | ||||||||||||
| Invitro | HUHS015 significantly suppresses the growth of DU145 cells, which are human hormone-independent prostate cancer cells[1]. | ||||||||||||
| In Vivo | HUHS015 potently suppresses the growth of DU145 cells in a mouse xenograft model[1].HUHS015 displays 7.2% bioavailability (BA) in rats after oral administration[1]. Animal Model: | ||||||||||||
| Name | HUHS015 | ||||||||||||
| CAS | 1453097-13-6 | ||||||||||||
| Formula | C19H18N4O | ||||||||||||
| Molar Mass | 318.37 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Nakao S et al. Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs. Bioorg Med Chem Lett, 2014 Feb 15, 24(4):1071-4. |